| EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, ... Nature cancer 2 (4), 444-456, 2021 | 138 | 2021 |
| Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. S Gupta, G Sonpavde, CJ Weight, BA McGregor, S Gupta, BL Maughan, ... Journal of Clinical Oncology 38 (6_suppl), 439-439, 2020 | 129 | 2020 |
| Low abundance of circulating tumor DNA in localized prostate cancer ST Hennigan, SY Trostel, NT Terrigino, OS Voznesensky, RJ Schaefer, ... JCO precision oncology 3, 2019 | 68 | 2019 |
| Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer S Awasthi, A Berglund, J Abraham-Miranda, RJ Rounbehler, K Kensler, ... Clinical Cancer Research 27 (1), 320-329, 2021 | 59 | 2021 |
| Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer RR McKay, W Xie, H Ye, FM Fennessy, Z Zhang, R Lis, C Calagua, ... The Journal of urology 206 (1), 80-87, 2021 | 47 | 2021 |
| Dying for advice: code status discussions between resident physicians and patients with advanced cancer—a national survey DJ Einstein, KL Einstein, P Mathew Journal of Palliative Medicine 18 (6), 535-541, 2015 | 45 | 2015 |
| Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) MB Atkins, OA Jegede, NB Haas, DF McDermott, MA Bilen, M Stein, ... Journal of Clinical Oncology 40 (25), 2913, 2022 | 40 | 2022 |
| Targeting the androgen receptor and overcoming resistance in prostate cancer DJ Einstein, S Arai, SP Balk Current opinion in oncology 31 (3), 175-182, 2019 | 36 | 2019 |
| Treatment approaches for cisplatin-ineligible patients with invasive bladder cancer DJ Einstein, G Sonpavde Current Treatment Options in Oncology 20, 1-13, 2019 | 27 | 2019 |
| Improving end-of-life care: palliative care embedded in an oncology clinic specializing in targeted and immune-based therapies DJ Einstein, S DeSanto-Madeya, M Gregas, J Lynch, DF McDermott, ... Journal of oncology practice 13 (9), e729-e737, 2017 | 26 | 2017 |
| A subset of localized prostate cancer displays an immunogenic phenotype associated with losses of key tumor suppressor genes C Calagua, M Ficial, CS Jansen, T Hirz, L Del Balzo, S Wilkinson, R Lake, ... Clinical Cancer Research 27 (17), 4836-4847, 2021 | 24 | 2021 |
| Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer JW Russo, X Liu, H Ye, C Calagua, S Chen, O Voznesensky, J Condulis, ... Cancer letters 438, 97-104, 2018 | 24 | 2018 |
| Hot or not: tumor mutational burden (TMB) as a biomarker of immunotherapy response in genitourinary cancers B Halbert, DJ Einstein Urology 147, 119-126, 2021 | 23 | 2021 |
| Autocrine canonical Wnt signaling primes noncanonical signaling through ROR1 in metastatic castration-resistant prostate cancer F Ma, S Arai, K Wang, C Calagua, AR Yuan, L Poluben, Z Gu, JW Russo, ... Cancer research 82 (8), 1518-1533, 2022 | 18 | 2022 |
| Assessment of molecular remission in oligometastatic esophageal cancer with a personalized circulating tumor DNA assay DJ Einstein, N Liang, M Malhotra, A Aleshin, S Moshkevich, PR Billings, ... JCO Precision Oncology 4, 239-243, 2020 | 15 | 2020 |
| Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer DJ Einstein, DF McDermott Clin Adv Hematol Oncol 15 (6), 478-488, 2017 | 15 | 2017 |
| Expanded Prostate Cancer Index Composite-26 (EPIC-26) online: validation of an internet-based instrument for assessment of health-related quality of life after treatment for … DJ Einstein, D Patil, J Chipman, MM Regan, K Davis, CM Crociani, ... Urology 127, 53-60, 2019 | 14 | 2019 |
| Phase I study of niraparib in combination with radium-223 for the treatment of metastatic castrate-resistant prostate cancer Z Quinn, B Leiby, G Sonpavde, AD Choudhury, C Sweeney, D Einstein, ... Clinical Cancer Research 29 (1), 50-59, 2023 | 11 | 2023 |
| Patient perceptions of treatment benefit and toxicity in advanced cancer: a prospective cross-sectional study R Patell, D Einstein, E Miller, L Dodge, J Halleck, M Buss JCO Oncology Practice 17 (2), e119-e129, 2021 | 11 | 2021 |
| The ethical imperative of healthy paternalism in advance directive discussions at the end of life DJ Einstein, K Ladin, P Mathew JAMA oncology 2 (4), 429-430, 2016 | 11 | 2016 |
